

**IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA**

PFIZER INC. and UCB PHARMA GMBH,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	Civil No. <u>1:15-cv-13 (Keeley)</u>
	)	
MYLAN PHARMACEUTICALS INC.,	)	Electronically Filed January 27, 2015
	)	
Defendant.	)	

**COMPLAINT**

Plaintiffs Pfizer Inc. and UCB Pharma GmbH (collectively, “Plaintiffs”), by their undersigned attorneys, for their Complaint against Defendant Mylan Pharmaceuticals Inc. (“Mylan”) allege:

**NATURE OF THE ACTION**

1. This is an action for patent infringement under the patent laws of the United States, Title 35 of the United States Code, arising from Mylan’s filing of an Abbreviated New Drug Application (“ANDA”) with the United States Food and Drug Administration (“FDA”), by which Mylan seeks approval to market a generic version of Pfizer Inc.’s pharmaceutical product, Toviaz<sup>®</sup>, prior to the expiration of United States Patent Nos. 6,858,650 (“the ‘650 patent”), 7,384,980 (“the ‘980 patent”), 7,855,230 (“the ‘230 patent”), 7,985,772 (“the ‘772 patent”), and 8,338,478 (“the ‘478 patent”), which cover, inter alia, Toviaz<sup>®</sup> and/or its use.

**THE PARTIES**

2. Plaintiff Pfizer Inc. (“Pfizer”) is a corporation organized and existing under the laws of the State of Delaware, having a place of business at 235 East 42nd Street, New York, New York 10017.

3. Plaintiff UCB Pharma GmbH (“UCB”) is an entity organized and existing under the laws of Germany, having a place of business at Alfred-Nobel-Strasse 10, Monheim, Germany 40789.

4. On information and belief, Mylan is a company organized and existing under the laws of the State of West Virginia, having a principal place of business at 781 Chestnut Ridge Road, Morgantown, West Virginia 26505-4310. On information and belief, Mylan is in the business of making and selling generic pharmaceutical products, which it develops, manufactures and distributes in the State of West Virginia. On further information and belief, Mylan has previously admitted that it is subject to this Court’s jurisdiction and has previously submitted to this Court’s jurisdiction. Mylan has purposefully availed itself of the jurisdiction of this Court by, inter alia, filing lawsuits in this District, and asserting counterclaims in lawsuits filed against it in this District.

**JURISDICTION AND VENUE**

5. This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

6. This Court has personal jurisdiction over Mylan by virtue of, inter alia, its presence in West Virginia, having conducted business in West Virginia and having derived substantial revenue therefrom, previously consenting to personal jurisdiction in this Court, and having engaged in systematic and continuous contacts with the State of West Virginia.

7. Venue is proper in this District pursuant to 28 U.S.C. §§ 1391 and 1400(b).

**THE PATENTS-IN-SUIT**

8. On February 22, 2005, the United States Patent and Trademark Office issued the '650 patent, entitled "Stable Salts of Novel Derivatives of 3,3-Diphenylpropylamines." At the time of its issue, the '650 patent was assigned to Schwarz Pharma AG. UCB, formerly known as Schwarz Pharma AG, currently holds title to the '650 patent, a copy of which is attached to this Complaint as Exhibit A. Pfizer is the exclusive licensee of the '650 patent.

9. On June 10, 2008, the United States Patent and Trademark Office issued the '980 patent, entitled "Derivatives of 3,3-Diphenylpropylamines." At the time of its issue, the '980 patent was assigned to Schwarz Pharma AG. UCB, formerly known as Schwarz Pharma AG, currently holds title to the '980 patent, a copy of which is attached to this Complaint as Exhibit B. Pfizer is the exclusive licensee of the '980 patent.

10. On December 21, 2010, the United States Patent and Trademark Office issued the '230 patent, entitled "Derivatives of 3,3-Diphenylpropylamines." At the time of its issue, the '230 patent was assigned to UCB, which currently holds title to the '230 patent. A copy of the '230 patent is attached to this Complaint as Exhibit C. Pfizer is the exclusive licensee of the '230 patent.

11. On July 26, 2011, the United States Patent and Trademark Office issued the '772 patent, entitled "Derivatives of 3,3-Diphenylpropylamines." At the time of its issue, the '772 patent was assigned to UCB, which currently holds title to the '772 patent. A copy of the '772 patent is attached to this Complaint as Exhibit D. Pfizer is the exclusive licensee of the '772 patent.

12. On December 25, 2012, the United States Patent and Trademark Office issued the '478 patent, entitled "Derivatives of 3,3-Diphenylpropylamines." At the time of its issue, the '478 patent was assigned to UCB, which currently holds title to the '478 patent. A copy of the '478 patent is attached to this Complaint as Exhibit E. Pfizer is the exclusive licensee of the '478 patent.

**TOVIAZ<sup>®</sup>**

13. Pfizer holds approved New Drug Application No. 022030 ("the Toviaz<sup>®</sup> NDA") for fesoterodine fumarate extended-release tablets, in 4 and 8 mg dosage strengths, which Pfizer sells under the trade name, Toviaz<sup>®</sup>.

14. Pursuant to 21 U.S.C. § 355(b)(1) and attendant FDA regulations, the '650, '980, '230, '772, and '478 patents are listed in the FDA publication, "Approved Drug Products with Therapeutic Equivalence Evaluations" (the "Orange Book"), with respect to Toviaz<sup>®</sup>.

**MYLAN'S ANDA**

15. On information and belief, Mylan has submitted ANDA No. 20-6701 ("Mylan's ANDA") to the FDA, pursuant to 21 U.S.C. § 355(j), seeking approval to market fesoterodine fumarate extended-release tablets in 4 and 8 mg dosage strengths ("Mylan's Product").

16. On information and belief, Mylan's ANDA refers to and relies upon the Toviaz<sup>®</sup> NDA and contains data that, according to Mylan, demonstrate the bioequivalence of Mylan's Product and Toviaz<sup>®</sup>.

17. By letter to Pfizer and UCB, dated December 11, 2014, Mylan stated that Mylan's ANDA contained certifications, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV), that the '650, '980, '230, '772, and '478 patents are invalid, unenforceable, or will not be infringed by the

commercial manufacture, use, or sale of Mylan's Product (the "Paragraph IV Certifications"). Mylan attached a memorandum to its December 11, 2015 letter, in which it alleged factual and legal bases for its Paragraph IV Certifications.

**COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 6,858,650**

18. Plaintiffs re-allege and incorporate by reference the allegations of paragraphs 1-17 of this Complaint.

19. Mylan has infringed the '650 patent, pursuant to 35 U.S.C. § 271(e)(2)(A), by submitting Mylan's ANDA, by which Mylan seeks approval from the FDA to sell, offer to sell, use, and/or engage in the commercial manufacture of Mylan's Product prior to the expiration of the '650 patent.

20. Mylan's sale, offer for sale, use, or commercial manufacture of Mylan's Product within the United States, or importation of Mylan's Product into the United States, during the term of the '650 patent would infringe the '650 patent under 35 U.S.C. §§ 271(a), (b), and/or (c).

21. Plaintiffs will be harmed substantially and irreparably if Mylan is not enjoined from infringing the '650 patent.

22. Plaintiffs have no adequate remedy at law.

23. Plaintiffs are entitled to a finding that this case is exceptional and to an award of attorneys' fees under 35 U.S.C. § 285.

**COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 7,384,980**

24. Plaintiffs re-allege and incorporate by reference the allegations of paragraphs 1-17 of this Complaint.

25. Mylan has infringed the '980 patent, pursuant to 35 U.S.C. § 271(e)(2)(A), by submitting Mylan's ANDA, by which Mylan seeks approval from the FDA to sell, offer to sell, use, and/or engage in the commercial manufacture of Mylan's Product prior to the expiration of the '980 patent.

26. Mylan's sale, offer for sale, use, or commercial manufacture of Mylan's Product within the United States, or importation of Mylan's Product into the United States, during the term of the '980 patent would infringe the '980 patent under 35 U.S.C. §§ 271(a), (b), and/or (c).

27. Plaintiffs will be harmed substantially and irreparably if Mylan is not enjoined from infringing the '980 patent.

28. Plaintiffs have no adequate remedy at law.

29. Plaintiffs are entitled to a finding that this case is exceptional and to an award of attorneys' fees under 35 U.S.C. § 285.

**COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 7,855,230**

30. Plaintiffs re-allege and incorporate by reference the allegations of paragraphs 1-17 of this Complaint.

31. Mylan has infringed the '230 patent, pursuant to 35 U.S.C. § 271(e)(2)(A), by submitting Mylan's ANDA, by which Mylan seeks approval from the FDA to sell, offer to sell, use, and/or engage in the commercial manufacture of Mylan's Product prior to the expiration of the '230 patent.

32. Mylan's sale, offer for sale, use, or commercial manufacture of Mylan's Product within the United States, or importation of Mylan's Product into the United States, during

the term of the '230 patent would infringe the '230 patent under 35 U.S.C. §§ 271(a), (b), and/or (c).

33. Plaintiffs will be harmed substantially and irreparably if Mylan is not enjoined from infringing the '230 patent.

34. Plaintiffs have no adequate remedy at law.

35. Plaintiffs are entitled to a finding that this case is exceptional and to an award of attorneys' fees under 35 U.S.C. § 285.

**COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 7,985,772**

36. Plaintiffs re-allege and incorporate by reference the allegations of paragraphs 1-17 of this Complaint.

37. Mylan has infringed the '772 patent, pursuant to 35 U.S.C. § 271(e)(2)(A), by submitting Mylan's ANDA, by which Mylan seeks approval from the FDA to sell, offer to sell, use, and/or engage in the commercial manufacture of Mylan's Product prior to the expiration of the '772 patent.

38. Mylan's sale, offer for sale, use, or commercial manufacture of Mylan's Product within the United States, or importation of Mylan's Product into the United States, during the term of the '772 patent would infringe the '772 patent under 35 U.S.C. §§ 271(a), (b), and/or (c).

39. Plaintiffs will be harmed substantially and irreparably if Mylan is not enjoined from infringing the '772 patent.

40. Plaintiffs have no adequate remedy at law.

41. Plaintiffs are entitled to a finding that this case is exceptional and to an award of attorneys' fees under 35 U.S.C. § 285.

**COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 8,338,478**

42. Plaintiffs re-allege and incorporate by reference the allegations of paragraphs 1-17 of this Complaint.

43. Mylan has infringed the '478 patent, pursuant to 35 U.S.C. § 271(e)(2)(A), by submitting Mylan's ANDA, by which Mylan seeks approval from the FDA to sell, offer to sell, use, and/or engage in the commercial manufacture of Mylan's Product prior to the expiration of the '478 patent.

44. Mylan's sale, offer for sale, use, or commercial manufacture of Mylan's Product within the United States, or importation of Mylan's Product into the United States, during the term of the '478 patent would infringe the '478 patent under 35 U.S.C. §§ 271(a), (b), and/or (c).

45. Plaintiffs will be harmed substantially and irreparably if Mylan is not enjoined from infringing the '478 patent.

46. Plaintiffs have no adequate remedy at law.

47. Plaintiffs are entitled to a finding that this case is exceptional and to an award of attorneys' fees under 35 U.S.C. § 285.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs pray for a judgment in their favor and against Mylan and respectfully request the following relief:

- A. A judgment that Mylan has infringed the '650 patent;
- B. A judgment that Mylan has infringed the '980 patent;
- C. A judgment that Mylan has infringed the '230 patent;
- D. A judgment that Mylan has infringed the '772 patent;



E. A judgment that Mylan has infringed the '478 patent;

F. A judgment, pursuant to 35 U.S.C. § 271(e)(4)(B) preliminarily and permanently enjoining Mylan, its officers, agents, servants, and employees, and those persons in active concert or participation with any of them, from manufacturing, using, offering to sell, or selling Mylan's Product within the United States, or importing Mylan's Product into the United States, prior to the expiration of the '650, '980, '230, '772, and '478 patents, including any extensions;

G. A judgment ordering that pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any approval of ANDA No. 20-6701, under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)), shall not be earlier than the expiration of the '650, '980, '230, '772, and '478 patents, including any extensions;

H. If Mylan commercially manufactures, uses, offers to sell, or sells Mylan's Product within the United States, or imports Mylan's Product into the United States, prior to the expiration of any of the '650, '980, '230, '772, and '478 patents, including any extensions, a judgment awarding Pfizer monetary relief, together with interest;

I. Attorneys' fees in this action as an exceptional case pursuant to 35 U.S.C. § 285;

J. Costs and expenses in this action; and

K. Such other relief as the Court deems just and proper.

PHILLIPS, GARDILL, KAISER & ALTMAYER, PLLC

/s/ William Kolibash

William Kolibash (#2087)  
61 Fourteenth Street  
Wheeling, WV 26003  
(304) 232-6810  
williamkolibash@pgka.com

*Attorneys for Pfizer Inc. and UCB Pharma GmbH*

OF COUNSEL:

Dimitrios T. Drivas  
Jeffrey J. Oelke  
James S. Trainor, Jr.  
Robert Counihan  
Ryan P. Johnson  
WHITE & CASE LLP  
1155 Avenue of the Americas  
New York, NY 10036  
(212) 819-8200

January 26, 2015